EN | RU
EN | RU

Help Support

Back

Tolerability and safety of Erenumab to treat migraine across different age groups

Episodic Migraine Episodic Migraine
Episodic Migraine Episodic Migraine

The safety and tolerability of Erenumab, a fully human monoclonal antibody, were examined in a pooled analysis of five large trials, with a focus on elderly people.

See All

Key take away

Erenumab is a well-tolerated and safe intervention for older patients diagnosed with chronic or episodic migraine.

Background

The safety and tolerability of Erenumab, a fully human monoclonal antibody, were examined in a pooled analysis of five large trials, with a focus on elderly people.

Method

Assessment of safety data from the 12-week double-blind treatment phase (DBTP) of 5 placebo-controlled randomized, Phase II and III trials of Erenumab in chronic or episodic migraine people was completed. Volunteers were segregated into different age groups of less than 40 years, 40-49 years, 50-59 years, and ≥ 60 years. By evaluating safety outcomes such as events resulting in discontinuation of study medication, serious adverse events (AEs), and treatment-emergent AEs, the safety of Erenumab across age groups were evaluated.

Result

A total of 3345 patients were randomly assigned to receive placebo, 70 mg Erenumab (n = 1132), or 140 mg Erenumab (n = 854) across five trials. Of these, 94.9% finished the DBTP (n = 3176). At least one dosage of Erenumab 70 mg, Erenumab 140 mg, and placebo was given to 1122 (33.8%), 850 (25.6%), and 1349 (40.6%) respectively.

For all doses of Erenumab (70 mg or 140 mg) and placebo, the occurrence of treatment-emergent AEs was comparable across all age groups (less than 40 years, 44.0% versus 44.4%; 40-49 years, 42.5% versus 49.2%; 50 to 59 years, 46.5% versus 41.6%; ≥ 60 years, 43.8% versus 59.4%). The occurrence of treatment-emergent serious AEs overall, and stratified by age groups for both dosages and placebo, was low (less than 40 years, 0.9% versus 1.2%; 40-49 years, 1.7% versus 1.9%; and 50-59 years, 1.6% versus 1.1%). No major serious AEs were observed in persons ≥ 60 years old. No fatalities were recorded.

Conclusion

In adults with episodic or chronic migraine, Erenumab (70 mg or 140 mg) displayed a comparable safety profile to placebo across age groups, with no raised emergence of events attributable to advancing age. In older adults with various comorbidities, polypharmacy, and age-linked physiological changes, Erenumab was well-tolerated.

Source:

The Journal of Headache and Pain

Article:

Safety and tolerability of Erenumab in individuals with episodic or chronic migraine across age groups: a pooled analysis of placebo-controlled trials

Authors:

Christian Lampl et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en ru ua
Try: